Full Text Journal Articles by
Author Millie D Long

Advertisement

Find full text journal articles






Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.

Millie D Long, Anita Afzali, Monika Fischer, David Hudesman, Maisa Abdalla, Robert McCabe, Benjamin L Cohen, Ryan C Ungaro, Will Harlan, John Hanson, Gauree Konijeti, Steven Polyak, Timothy Ritter, Bruce Salzberg, Jennifer Seminerio, Emily English, Xian Zhang, Puza P Sharma, Hans H Herfarth,

<h4>Background</h4>Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Using a novel electronic reporting tool, we aimed to prospectively describe the onset of tofacitinib efficacy during induction therapy in a real-world study.<h4>Methods</h4>Patient-reported outcome data (PROs) including the simple clinical colitis activity index (SCCAI), PRO Measurement ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2022, :izac121]

Cited: 0 times

View full text PDF listing >>



Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.

Kevin L Winthrop, Séverine Vermeire, Millie D Long, Julian Panés, Siew C Ng, Nicole Kulisek, Rajiv Mundayat, Nervin Lawendy, Ivana Vranic, Irene Modesto, Chinyu Su, Gil Y Melmed,

<h4>Background</h4>Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report herpes zoster (HZ) incidence and risk factors in the tofacitinib UC clinical program (up to 7.8 years).<h4>Methods</h4>Proportions and incidence rates (IRs; unique patients with events/100 patient-years) of HZ were evaluated in 4 ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2022, :izac063]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

0.4724 s